<p><span class="postbody"><span class="postbody"><a href="http://www.docguide.com/news/content.nsf/news/852571020057CCF68525728A0056E3F7" target="_blank"><font color="#000066">http://www.docguide.com/news/content.nsf/news/852571020057CCF68525728A0056E3F7</font></a>
<br/><br/>BASEL, SWITZERLAND – February 22, 2007 -- A phase III study of Avastin (bevacizumab) and chemotherapy improved progression free survival in patients with previously untreated advanced non-small cell lung cancer (NSCLC), the most common form of the disease. <br/><br/>This benefit was seen in patients who received either one of two different Avastin doses investigated in the trial. <br/><br/>The results show that Avastin administered in a schedule of either 7.5 or 15 mg/kg every 3 weeks in combination with gemcitabine/cisplatin chemotherapy significantly prolonged the time patients with advanced NSCLC lived without their disease progressing when compared to chemotherapy alone. <br/><br/>Although the study was not designed to compare the Avastin doses, a similar treatment effect in progression-free survival was observed between the two arms. The benefit and relative safety of each arm will be presented at an upcoming medical meeting. There were no new safety signals associated with the use of Avastin at either dose in this clinical setting. <br/><br/>The study is an international Phase III trial which includes more than 1,000 patients with previously untreated advanced NSCLC, the most common form of lung cancer, with histology other than predominant squamous cell. The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms versus the control regimen.<br/></span></span></p>
<p>lease see more information below:</p><p><span class="posted" nd="1">osted on: Friday, 13 October 2006, 06:00 CDT</span>
</p><h1>Avastin Approved for Lung Cancer</h1><p nd="2">The FDA has approved Genentech's cancer drug Avastin to be used in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of patients with lung cancer. </p><p nd="3">Avastin will be used to specifically target non-small cell lung cancer, the most common type of lung cancer. The approval is based on a phase III study that showed Avastin in combination with chemotherapy resulted in a 25% improvement in overall survival compared to chemotherapy alone. </p><p nd="4">"Bevacizumab, in combination with chemotherapy, is the first therapy in 10 years to improve on standard first-line treatment for advanced lung cancer and the first FDA-approved therapy ever to extend survival for these patients beyond one year," said Alan Sandler, director of Medical Thoracic Oncology at Vanderbilt-Ingram Cancer Center. </p><div style="FLOAT: right; MARGIN: 10px 0px 10px 10px; WIDTH: 300px;"><script language="JavaScript" src="http://an.tacoda.net/an/11620/slf.js"></script><script language="JavaScript"></script><script language="JavaScript" src="http://anad.tacoda.net/cgi-bin/ads/ad11620a.cgi/v=2.1S/sz=300x250a/NZ/91560/NF/RETURN-CODE/JS/"></script><a href="http://anad.tacoda.net/ads/ad11620a-map.cgi/BCPG65771.94390.107785/SZ=300X250A/V=2.1S//REDIRURL=http://www.emcinsignia.com/en/promos/retrospect/?utm_id=119" target="_blank"></a></div><p nd="5">Genentech also said that it plans to initiate a first-of-its-kind program to cap the overall expense of Avastin to $55,000 per year per eligible patient for any FDA-approved indication. </p><p nd="6">The price of Avastin was established in February 2004 upon the FDA approval of the drug for the treatment of first-line colorectal cancer in combination with chemotherapy. At that time, the monthly price of Avastin was set below the standard of care chemotherapy for metastatic colorectal cancer at approximately $4,400. </p><p nd="7">In advanced lung cancer, a higher dose of Avastin is indicated which means the monthly price of Avastin has to be increased. </p><p nd="8">"The new expenditure cap on Avastin is a step Genentech is taking to address this variability in current and future FDA-approved indications," said Arthur Levinson, Genentech's chairman and CEO.</p><p><br/></p><p nd="9">Source: Datamonitor</p>